GINA 2026 Report Updates Asthma Treatment Pathways and Exacerbation Care

The 2026 GINA Strategy Report updates its evidence-based approach to asthma diagnosis, treatment, and prevention, maintaining its Assess-Adjust-Review cycle for symptom control and risk reduction. GINA recommends ICS-containing treatment for nearly all patients and advises against SABA-only therapy, with low-dose ICS-formoterol as-needed or as maintenance-and-reliever therapy preferred for adults and adolescents due to reduced severe exacerbations compared with SABA-based regimens. The report states that 2026 updates include expanded anti-inflammatory reliever options, revised severe asthma and biologic selection guidance, and substantial changes to acute asthma management.

Most relevant for: Patients of all ages with asthma, including those with difficult-to-treat or severe asthma and those presenting with acute exacerbations.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.